PMID- 11830433
OWN - NLM
STAT- MEDLINE
DCOM- 20020308
LR  - 20190503
IS  - 0003-4967 (Print)
IS  - 1468-2060 (Electronic)
IS  - 0003-4967 (Linking)
VI  - 61
IP  - 3
DP  - 2002 Mar
TI  - Soluble tumour necrosis factor receptor treatment does not affect raised 
      transforming growth factor beta levels in rheumatoid arthritis.
PG  - 254-6
AB  - OBJECTIVE: To further elucidate the immunomodulating effects of anti-tumour 
      necrosis factor alpha treatment in rheumatoid arthritis (RA) by studying changes 
      in plasma levels of transforming growth factor beta (TGFbeta) in patients with RA 
      undergoing etanercept treatment. METHODS: Plasma levels of TGFbeta1 and TGFbeta2 
      were determined in 26 patients with RA during six months of etanercept treatment 
      and compared with disease activity and laboratory parameters, including matrix 
      metalloproteinase-3 (MMP-3) and interleukin 6 (IL6). RESULTS: Before treatment 
      all patients had raised TGFbeta1, IL6, and MMP-3 levels. In the course of 
      treatment IL6 and MMP-3 levels decreased significantly, accompanied by a drop in 
      serological markers (C reactive protein and erythrocyte sedimentation rate) and 
      clinical disease activity (visual analogue scale and Thompson joint score). By 
      contrast, high levels of latent TGFbeta1 were present in all specimens over the 
      entire six months. TGFbeta2 levels did not change during treatment. CONCLUSION: 
      Etanercept treatment induces subtle changes in the cytokine network. Although the 
      proinflammatory cytokine IL6 is down regulated, the persistence of high TGFbeta 
      plasma levels indicates the existence of as yet unknown mechanisms for TGFbeta 
      overexpression in RA. This may predispose to severe infections and can cause an 
      altered tumour defence.
FAU - Drynda, S
AU  - Drynda S
AD  - Clinic of Rheumatology, Otto-von-Guericke-University Magdeburg, 39245 
      Vogelsang/Magdeburg, Germany.
FAU - Kuhne, C
AU  - Kuhne C
FAU - Kekow, J
AU  - Kekow J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Ann Rheum Dis
JT  - Annals of the rheumatic diseases
JID - 0372355
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Interleukin-6)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - 0 (Transforming Growth Factor beta)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
RN  - OP401G7OJC (Etanercept)
SB  - IM
CIN - Ann Rheum Dis. 2002 Jul;61(7):667; author reply 667. PMID: 12079925
MH  - Antirheumatic Agents/*therapeutic use
MH  - Arthritis, Rheumatoid/*blood/*drug therapy
MH  - Blood Sedimentation
MH  - C-Reactive Protein/analysis
MH  - Case-Control Studies
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Etanercept
MH  - Female
MH  - Humans
MH  - Immunoglobulin G/*therapeutic use
MH  - Interleukin-6/blood
MH  - Male
MH  - Matrix Metalloproteinase 3/blood
MH  - Middle Aged
MH  - Pain Measurement
MH  - Receptors, Tumor Necrosis Factor/*therapeutic use
MH  - Statistics, Nonparametric
MH  - Transforming Growth Factor beta/*blood
PMC - PMC1754023
EDAT- 2002/02/07 10:00
MHDA- 2002/03/09 10:01
PMCR- 2005/03/01
CRDT- 2002/02/07 10:00
PHST- 2002/02/07 10:00 [pubmed]
PHST- 2002/03/09 10:01 [medline]
PHST- 2002/02/07 10:00 [entrez]
PHST- 2005/03/01 00:00 [pmc-release]
AID - 10.1136/ard.61.3.254 [doi]
PST - ppublish
SO  - Ann Rheum Dis. 2002 Mar;61(3):254-6. doi: 10.1136/ard.61.3.254.